MoonLake Immunotherapeutics MLTX
$11.07 +$0.04 (+0.36%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $11.07 0.00%
Open$10.79
Prev close$11.03
Day range$10.73 – $11.31
Volume1.72M
Market cap$942.13M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$79.85M-11.8% YoY
Net profit-$79.55M-12.5% YoY
Diluted EPS-$0.93+15.5% YoY
Free cash flow-$63.40M-42.3% YoY
Operating cash flow-$63.40M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-81.6%
Return on assets-57.3%
Return on invested capital-63.2%
Current ratio9.13
Liabilities / assets29.4%
Cash & investments$498.46M
Total debt$100.66M
Net cash (debt)$397.81M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $79.85M | $61.66M | $70.02M | $244.83M | $65.22M |
| Selling and Admin Expenses | $10.98M | $11.44M | $15.51M | $41.97M | $9.21M |
| -General & Admin Expense | $10.98M | $11.44M | $15.51M | $41.97M | $9.21M |
| Research & Development | $68.87M | $50.22M | $54.52M | $202.86M | $56.01M |
| Operating Profit | -$79.85M | -$61.66M | -$70.02M | -$244.83M | -$65.22M |
| Net Non-Operating Interest Income (Expense) | -$2.66M | -$2.63M | -$2.27M | -$7.25M | -$1.99M |
| Non-Operating Interest Expense | $2.66M | $2.63M | $2.27M | $7.25M | $1.99M |
| Other Income (Expense) | $3.59M | $2.58M | $3.21M | $22.37M | $4.44M |
| Gain on Sale of Security | -$212,000.00 | -$294,000.00 | – | – | – |
| Other Non-Operating Income (Expenses) | $3.81M | $2.87M | $3.21M | $22.37M | $4.37M |
| Pretax Profit | -$78.91M | -$61.72M | -$69.09M | -$229.71M | -$62.77M |
| Tax | $631,000.00 | $90,000.00 | $622,000.00 | $611,000.00 | $248,000.00 |
| Net Profit | -$79.55M | -$61.81M | -$69.71M | -$230.32M | -$63.02M |
| Profit from Continuing Operations | -$79.55M | -$61.81M | -$69.71M | -$230.32M | -$63.02M |
| Minority Interests | $0.00 | $0.00 | $0.00 | -$3.00M | -$591,000.00 |
| Net Income to Parent Company | -$79.55M | -$61.81M | -$69.71M | -$227.32M | -$62.43M |
| Net Income to Common Stockholders | -$79.55M | -$61.81M | -$69.71M | -$227.32M | -$62.43M |
| Basic EPS | -$0.93 | -$0.84 | -$0.98 | -$3.53 | -$0.92 |
| Diluted EPS | -$0.93 | -$0.84 | -$0.98 | -$3.53 | -$0.92 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $540.72M | $573.95M | $400.37M | $424.43M | $424.43M |
| Total Current Assets | $533.34M | $570.04M | $396.64M | $421.69M | $421.69M |
| Cash and Cash Equivalents & Short-Term Investments | $498.46M | $537.03M | $357.92M | $393.97M | $393.97M |
| -Cash and Cash Equivalents | $379.70M | $477.91M | $298.49M | $334.52M | $334.52M |
| -Short Term Investments | $118.76M | $59.13M | $59.43M | $59.45M | $59.45M |
| Receivables | $8.95M | $6.56M | $5.76M | $4.87M | $4.87M |
| -Other Receivables | $8.95M | $6.56M | $5.76M | $4.87M | $4.87M |
| Prepaid Assets | $25.93M | $26.45M | $32.96M | $22.86M | $22.86M |
| Total Non-Current Assets | $7.37M | $3.91M | $3.73M | $2.74M | $2.74M |
| Net PPE | $2.16M | $2.57M | $2.39M | $2.14M | $2.14M |
| -Gross PPE | $2.16M | $2.57M | $2.39M | $2.14M | $2.14M |
| Other Non-Current Assets | $5.22M | $1.34M | $1.34M | $596,000.00 | $596,000.00 |
| Total Liabilities | $159.09M | $145.75M | $146.35M | $119.95M | $119.95M |
| Total Current Liabilities | $58.43M | $45.39M | $46.11M | $45.48M | $45.48M |
| Payables | $14.53M | $19.38M | $24.78M | $30.65M | $30.65M |
| -Accounts Payable | $13.85M | $17.04M | $23.38M | $28.43M | $28.43M |
| -Total Tax Payable | $682,000.00 | $2.35M | $1.40M | $1.09M | $1.09M |
| Current Accrued Expenses | $39.12M | $22.15M | $18.22M | $11.27M | $11.27M |
| Short-Term Debt and Capital Lease Obligation | $959,000.00 | $1.25M | $920,000.00 | $1.23M | $1.23M |
| -Current Capital Lease Obligation | $959,000.00 | $1.25M | $920,000.00 | $1.23M | $1.23M |
| Total Non-Current Liabilities | $100.66M | $100.36M | $100.24M | $74.47M | $74.47M |
| Long Term Debt and Capital Lease Obligation | $100.66M | $100.29M | $99.88M | $74.47M | $74.47M |
| -Long Term Debt | $100.01M | $99.51M | $99.02M | $74.10M | $74.10M |
| -Long Term Capital Lease Obligation | $647,000.00 | $772,000.00 | $865,000.00 | $374,000.00 | $374,000.00 |
| Total Equity | $381.63M | $428.20M | $254.02M | $304.48M | $304.48M |
| Stockholders' Equity | $381.63M | $428.20M | $254.02M | $304.48M | $304.48M |
| Capital Stock | $8,000.00 | $8,000.00 | $7,000.00 | $7,000.00 | $7,000.00 |
| -Common Stock | $8,000.00 | $8,000.00 | $7,000.00 | $7,000.00 | $7,000.00 |
| Additional Paid-In Capital | $1.05B | $1.02B | $786.31M | $766.78M | $766.78M |
| Retained Earnings | -$673.97M | -$594.42M | -$532.62M | -$462.91M | -$462.91M |
| Gains/Losses Not Affecting Retained Earnings | $2.29M | $630,000.00 | $322,000.00 | $604,000.00 | $604,000.00 |
| Employee Benefits | – | $74,000.00 | $353,000.00 | $0.00 | $0.00 |
| -Other Payable | – | – | – | $1.13M | $1.13M |
| Minority Interests | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$63.40M | -$55.56M | -$66.29M | -$196.01M | -$58.79M |
| Net cash flow from continuing operations | -$63.40M | -$55.56M | -$66.29M | -$196.01M | -$58.79M |
| Net Income from Continuing Operations | -$79.54M | -$61.81M | -$69.71M | -$230.32M | -$63.02M |
| Gain/Loss from Continuing Operations | -$4,000.00 | $9,000.00 | $11,000.00 | -$58,000.00 | -$31,000.00 |
| Depreciation & Depletion & Amortization | $905,000.00 | $896,000.00 | $845,000.00 | $2.62M | $751,000.00 |
| Other Non-Cash Items | $742,000.00 | $19,000.00 | $422,000.00 | -$1.02M | -$92,000.00 |
| Change in Working Capital | $11.65M | $2.78M | -$11.21M | $19.88M | $6,000.00 |
| -Change in Prepaid Assets | $514,000.00 | $6.51M | -$10.10M | $561,000.00 | $3.86M |
| -Change in Payables and Accrued Expense | $14.83M | -$2.55M | $950,000.00 | $23.15M | -$2.63M |
| -Change in Other Current Assets | -$4.97M | $9,000.00 | -$779,000.00 | -$587,000.00 | $1.18M |
| -Change in Other Current Liabilities | -$412,000.00 | -$395,000.00 | -$389,000.00 | -$1.22M | -$377,000.00 |
| Net cash flow from investing | -$58.76M | $322,000.00 | $98,000.00 | $202.99M | -$29.91M |
| Net Cash Flow from Continuing Investing Activities | -$58.76M | $322,000.00 | $98,000.00 | $202.99M | -$29.91M |
| Net PPE Purchase and Sale | $0.00 | $0.00 | $0.00 | -$35,000.00 | $0.00 |
| Net Investment Purchase and Sale | -$58.76M | $322,000.00 | $98,000.00 | $203.03M | -$29.91M |
| Financing Cash Flow | $26.97M | $234.62M | $30.64M | $146.00M | $72.40M |
| Net Cash Flow from Continuing Financing Activities | $26.97M | $234.62M | $30.64M | $146.00M | $72.40M |
| Net Issuance Payments Of Debt | $0.00 | $0.00 | $24.47M | $73.02M | $0.00 |
| Net Common Stock Issuance | $0.00 | $234.07M | $6.01M | $72.40M | $72.40M |
| Proceeds from Stock Option Exercised | $28.47M | $551,000.00 | $170,000.00 | $580,000.00 | $0.00 |
| Ending Cash Balance | $382.69M | $477.91M | $298.49M | $334.52M | $334.52M |
| Net Change in Cash | -$95.20M | $179.39M | -$35.54M | $152.98M | -$16.31M |
| Beginning Cash Balance | $477.91M | $298.49M | $334.52M | $180.43M | $350.74M |
| Effect of Exchange Rate Changes | -$24,000.00 | $29,000.00 | -$483,000.00 | $1.11M | $91,000.00 |
| Free Cash Flow | -$63.40M | -$55.56M | -$66.29M | -$196.04M | -$58.79M |
| -Change in Receivables | – | -$798,000.00 | -$894,000.00 | -$2.03M | -$847,000.00 |
No comments yet — be the first to weigh in on MLTX.
Sign in to join the discussion.